What is HC Wainwright’s Estimate for NRXP FY2026 Earnings?

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) – Stock analysts at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for NRx Pharmaceuticals in a research report issued on Tuesday, March 3rd. HC Wainwright analyst P. Trucchio now forecasts that the company will earn $0.13 per share for the year, up from their previous forecast of $0.12. HC Wainwright has a “Buy” rating and a $45.00 price objective on the stock. The consensus estimate for NRx Pharmaceuticals’ current full-year earnings is ($1.75) per share. HC Wainwright also issued estimates for NRx Pharmaceuticals’ Q4 2026 earnings at $0.06 EPS, FY2027 earnings at $1.23 EPS, FY2028 earnings at $3.18 EPS and FY2029 earnings at $5.06 EPS.

Other research analysts have also recently issued research reports about the company. Wall Street Zen upgraded NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, November 23rd. Zacks Research upgraded shares of NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, March 2nd. Weiss Ratings reiterated a “sell (e+)” rating on shares of NRx Pharmaceuticals in a research report on Monday, December 29th. D. Boral Capital restated a “buy” rating and issued a $34.00 target price on shares of NRx Pharmaceuticals in a research report on Tuesday, February 17th. Finally, Ascendiant Capital Markets reaffirmed a “buy” rating and set a $48.00 target price (up from $47.00) on shares of NRx Pharmaceuticals in a research note on Friday, January 2nd. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $38.00.

NRx Pharmaceuticals Stock Down 4.0%

Shares of NRXP stock opened at $1.70 on Thursday. NRx Pharmaceuticals has a twelve month low of $1.58 and a twelve month high of $3.84. The company has a market cap of $54.18 million, a P/E ratio of -0.72 and a beta of 1.97. The business has a fifty day simple moving average of $2.08 and a 200 day simple moving average of $2.49.

Hedge Funds Weigh In On NRx Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in NRXP. Ethos Financial Group LLC acquired a new position in shares of NRx Pharmaceuticals during the third quarter worth $39,000. Sjbenen Advisory LLC bought a new stake in shares of NRx Pharmaceuticals in the 4th quarter valued at about $41,000. One Wealth Management Investment & Advisory Services LLC increased its stake in shares of NRx Pharmaceuticals by 86.1% in the third quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock valued at $92,000 after buying an additional 12,950 shares during the period. Global Retirement Partners LLC acquired a new stake in NRx Pharmaceuticals during the 4th quarter valued at approximately $107,000. Finally, Two Sigma Investments LP raised its holdings in NRx Pharmaceuticals by 66.4% during the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after purchasing an additional 20,880 shares during the last quarter. 4.27% of the stock is currently owned by institutional investors and hedge funds.

NRx Pharmaceuticals News Summary

Here are the key news stories impacting NRx Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised multi‑year EPS forecasts and reiterated a Buy rating with a $45 price target — the firm boosted Q4 2026 to $0.06 (from $0.04) and lifted FY2026–FY2029 estimates (FY2026 $0.13, FY2027 $1.23, FY2028 $3.18, FY2029 $5.06), signaling strong expected growth and large upside vs. current market cap. HC Wainwright Forecasts Strong Price Appreciation for NRx Pharmaceuticals (NASDAQ:NRXP) Stock
• Neutral Sentiment: NRx is scheduled to report quarterly results on Friday — the print will be the immediate catalyst. With consensus full‑year EPS still negative (-$1.75), the market will focus on near‑term revenue, cash runway, and pipeline progress vs. HC Wainwright’s more optimistic multi‑year outlook. NRx Pharmaceuticals (NRXP) Expected to Announce Earnings on Friday
• Negative Sentiment: An analyst trimmed the Q3 EPS estimate for NRx, a near‑term downgrade that likely contributed to selling pressure today — this reduces near‑term expectations and raises the bar for the upcoming report. Investors should watch whether the earnings release justifies or reverses that cut. Q3 EPS Estimate for NRx Pharmaceuticals Decreased by Analyst

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.